Laboratory of Immune Regulation, Convergent Research Consortium for Immunologic Disease, Seoul, Korea.
Korean J Intern Med. 2013 Jul;28(4):387-402. doi: 10.3904/kjim.2013.28.4.387. Epub 2013 Jul 1.
Mesenchymal stem cells (MSCs) are self-renewing, multipotent progenitor cells with multilineage potential to differentiate into cell types of mesodermal origin, such as adipocytes, osteocytes, and chondrocytes. In addition, MSCs can migrate to sites of inflammation and exert potent immunosuppressive and anti-inflammatory effects through interactions between lymphocytes associated with both the innate and adaptive immune system. Along with these unique therapeutic properties, their ease of accessibility and expansion suggest that use of MSCs may be a useful therapeutic approach for various disorders. In the clinical setting, MSCs are being explored in trials of various conditions, including orthopedic injuries, graft versus host disease following bone marrow transplantation, cardiovascular diseases, autoimmune diseases, and liver diseases. Furthermore, genetic modification of MSCs to overexpress antitumor genes has provided prospects for clinical use as anticancer therapy. Here, we highlight the currently reported uses of MSCs in clinical trials and discuss their efficacy as well as their limitations.
间充质干细胞(MSCs)是自我更新的多能祖细胞,具有多向分化潜能,可分化为中胚层来源的细胞类型,如脂肪细胞、成骨细胞和成软骨细胞。此外,MSCs 可以迁移到炎症部位,并通过与先天和适应性免疫系统相关的淋巴细胞之间的相互作用,发挥强大的免疫抑制和抗炎作用。除了这些独特的治疗特性外,它们易于获取和扩增的特性表明,MSCs 的使用可能是治疗各种疾病的一种有用的治疗方法。在临床环境中,MSCs 正在各种疾病的临床试验中进行探索,包括骨科损伤、骨髓移植后移植物抗宿主病、心血管疾病、自身免疫性疾病和肝脏疾病。此外,通过基因修饰 MSCs 过表达抗肿瘤基因,为临床应用作为抗癌治疗提供了前景。在这里,我们重点介绍 MSCs 在临床试验中的目前报道用途,并讨论其疗效及其局限性。